[Federal Register Volume 66, Number 86 (Thursday, May 3, 2001)]
[Notices]
[Page 22235]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-11067]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Request for Input on Vaccine Financing

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (DHHS).

ACTION: Notice and request for public comment.

-----------------------------------------------------------------------

SUMMARY: The National Vaccine Advisory Committee (NVAC) Work Group on 
the Introduction of New Vaccines seeks input on issues that may be 
barriers to the optimal implementation of new vaccines. The work group 
is evaluating how vaccine financing affects the standard of care for 
different population subgroups.
    Vaccine financing can impact specific population subgroups 
differentially in terms of access and supply of new vaccines. The 
process by which the public and private sector purchase and distribute 
vaccines may differ in important ways. The public sector plays a major 
role in the financing of pediatric vaccine, but it plays a smaller role 
in the financing of adult vaccines. The timing of public purchase may 
depend on specific advisory group recommendations as well as specific 
state budgets. The eligibility for public and private payer programs 
may also vary.
    We are asking partner organizations and groups to submit their 
items on the pluses and minuses of the current vaccine financing 
system. In addition to identifying potential barriers to the optimal 
implementation of vaccines due to vaccine financing, possible solutions 
to these problems are requested. The information gathered from the 
partners will be used as the basis for a meeting to develop options for 
the NVAC to consider.

DATES: Comments and information must be submitted by May 31, 2001.

ADDRESSES: Comments and information regarding Vaccine Financing should 
be submitted to the National Vaccine Program Office, Attn: Introduction 
of New Vaccines, Centers for Disease Control and Prevention, Mailstop 
D-66, 1600 Clifton Road, NE., Atlanta, Georgia 30333; Federal Express 
Address: 200 E. Ponce de Leon Avenue, Decatur, Georgia 30030; fax: 404-
687-6687; e-mail: <a href="/cdn-cgi/l/email-protection#d8b6aea8b798bbbcbbf6bfb7ae"><span class="__cf_email__" data-cfemail="442a32342b042720276a232b32">[email protected]</span></a>.

FOR FURTHER INFORMATION CONTACT: The National Vaccine Program Office, 
Attn: Introduction of New Vaccines, Centers for Disease Control and 
Prevention, Mailstop D-66, 1600 Clifton Road, NE., Atlanta, Georgia 
30333; Federal Express Address: 200 E. Ponce de Leon Avenue, Decatur, 
Georgia 30030; fax: 404-687-6687; e-mail: <a href="/cdn-cgi/l/email-protection#29475f5946694a4d4a074e465f"><span class="__cf_email__" data-cfemail="b9d7cfc9d6f9daddda97ded6cf">[email protected]</span></a>.

    Dated: April 27, 2001.
Joseph R. Carter,
Associate Director for Management and Operations, Centers for Disease 
Control and Prevention.
[FR Doc. 01-11067 Filed 5-2-01; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>